• Oramed Initiates Second Phase 3 Oral Insulin Study americanpharmaceuticalreview
    March 30, 2021
    Oramed Pharmaceuticals has screened the first patients in its ORA-D-013-2 study, the second of two concurrent Phase 3 studies of its oral insulin capsule, ORMD-0801, for the treatment of type 2 diabetes (T2D).
PharmaSources Customer Service